ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity

Biology of Reproduction

Volumn 54, Issue 1, 1996, Pages 160-167

  Branham, William S ^a   Fishman, Renata ^a   Streck, Randal D ^a   Medlock, Kevin L ^a   DeGeorge, Joseph J ^b   Sheehan, Daniel M ^a  

^a Natl Ctr Toxicological Res F   (United States)

^b Ctr for Drug Eval and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN; TAMOXIFEN CITRATE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIUM; FEMALE; IMMUNOHISTOCHEMISTRY; MICROSCOPY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS; UTERUS GROWTH; UTERUS WEIGHT;

ANIMAL; EPITHELIUM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; IMMUNOHISTOCHEMISTRY; ORGAN WEIGHT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; UTERUS;

ANIMALIA;

EID: 0029655594     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod54.1.160     Document Type: Article

References (49)

1. Jordan VC, Murphy CS Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990, 11 578-610
2. Jordan VC The role of tamoxifen in the treatment and prevention of breast cancer Curr Probl Cancer 1992, 16:134-176
3. Killackey MA, Hakes TB, Pierce VK Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens Cancer Treat Rep 1985; 69:237-238
4. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium Lancet 1989, 1.375
5. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy Obstet Gynecol 1992; 79.111-116.
6. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapv for breast cancer. Gynecol Oncol 1992; 45:118-128.
7. Kedar RP, Bourne TH, Powles TJ, Cotlins WP Ashley SE, Cosgrove DO, Campbell S Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994, 343 1318-1321.
8. Goddard MK. Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits. Br J Med Prac 1992, 42:120-125.
9. Branham WS, Zehr DR, Sheehan DM. Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens Proc Soc Exp Biol Med 1993; 203:297-303.
10. Fromson JM, Pearson S, Bramah (nee Meek) S. The metabolism of tamoxifen (I C I 46,474) I In laboratory animals Xenobiotica 1973; 3 693-709.
11. Fromson JM, Pearson S, Bramah (nee Meek) S. The metabolism of tamoxifen (I C I. 46,474) II In female patients Xenobiotica 1973; 3:711-714
12. Mikkelson TJ Krohoth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ Single-dose pharmacokinetics of clomiphene citrate in normal volunteers Fertil Steril 1986, 46 392-396
13. Kaufman RH, Adam E, Binder GL, Gerthofter E Upper genital tract changes and pregnancy outcome in offspring exposed m utero to diethylstilbestrol. Am J Obstet 1980; 137:299-308
14. Ben-Baruch G, Menczer J, Mashiach S, Serr DM. 1981 Uterine anomalies in diethylstilbestrol-exposed women with fertility disorders. Acta Obstet Gynecol Scand 1980, 60.395-397.
15. Branham WS, Sheehan DM, Zehr DR, Medlock KL, Nelson CJ, Ridlon E Inhibition of uterine gland genesis by tamoxifen Endocrinology 1985, 117 2238-2248
16. Branham WS, Zehr DR, Chen JJ, Sheehan DM Uterine abnormalities in rats exposed neonatally to diethylsulbestrol, ethynylestradiol, or clomiphene citrate Toxicology 1988 51 201-212
17. Branham WS, Zehr DR, Chen JJ, Sheehan DM. Alterations in developing rat uterine cell populations after neonatal exposure to estrogens and antiestrogens Teratology 1988, 38:271-279
18. Taguchi O, Nishizuka Y. Reproductive tract abnormalities in female mice treated neonatally with tamoxifen Am J Obstet Gynecol 1985, 151:675-678.
19. Iguchi T, Hirokawa M, Takasugi N Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen Toxicology 1986; 42:1-11.
20. Iguchi T, Todoroki R, Yamaguchi S, Takasugi N. Changes in the uterus and vagina of mice treated neonatally with antiestrogens. Acta Anat 1989; 136:146-154
21. Branham WS, Sheehan DM, Zehr DR, Ridlon E, Nelson CJ. The postnatal ontogeny of uterine glands and age-related effects of 17β-estradiol Endocrinology 1985; 117:2229-2237.
22. Plagge JE Effect of prepuberal castration on body and thymus weight in the immature albino rat Anat Rec 1956, 128:101-110
23. Baker FD, Kragt CL. Maturation of the hypothalamic-pituitary-gonadalnegative feedback system Endocrinology 1969; 85 522-527
24. Reiter EO, Goldenberg RL, Vaitukaitis JL, Ross GT. A role for endogenous estrogen in normal ovarian development in the neonatal rat Endocrinology 1972; 91 1537-1539.
25. Branham WS, Sheehan DM. Ovarian and adrenal contributions to postnatal growth and differentiation of the rat uterus Biol Reprod 1995; 53:871-880.
26. Wakeling AE, Bowler J Novel antioestrogens without partial agonist activity J Steroid Biochem 1988, 31 645-653
27. Wakeling AE, Bowler J ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 1992; 43:173-177.
28. Lykkesfeldt AE, Sorenson EK. Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 1992, 31.131-138.
29. Berry M, Metzger D, Chambon P Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen EMBO J 1990, 9 2811-2818
30. Gibson MK, Nemmers LA, Beckman WC, Davis VL, Curtis SW, Korach KS The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue Endocrinology 1991, 129 2000-2010
31. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 104,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992; 89 4037-4041
32. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization Proc Natl Acad Sci USA 1990, 87:6883-6887.
33. Arbuckle ND, Dauvois S, Parker MG. Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucleic Acids Res 1992; 20 3839-3844
34. Reese JC, Katzenellenbogen BS. Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for the hormone-dependent transactivation and actions of antiestrogens. Mol Cell Biol 1992; 12 4531-4538.
35. Dauvois S, White R, Parker MG The antiestrogen ICI 182,780 disrupts estrogen receptor nucleoplasmic shuttling J Cell Sci 1993, 106:1377-1388.
36. Wakeling AE, Dukes M, Bowler J A potent specific pure antiestrogen with clinical potential Cancer Res 1991, 51:3807-3873
37. Dohler KD, Wuttke W Changes with age in levels of serum gonadotropins, prolactin, and gonadal steroids in prepubertal male and female rats. Endocrinology 1975; 97:898-907.
38. Medlock KL, Sheehan DM, Branham WS The postnatal ontogeny of the rat uterine estrogen receptor. J Steroid Biochem 1981, 15:285-288
39. Medlock KL, Sheehan DM, Nelson CJ, Branham WS. Effect of postnatal DES treatment on uterine growth, development and estrogen receptor levels. J Steroid Biochem 1988; 29:527-532
40. Greco TL, Furlow JD, Duello TM, Gorski J. Immunodetection of estrogen receptors in fetal and neonatal female mouse reproductive tracts Endocrinology 1991; 129:1326-1332
41. Yamashita S, Newbold RR, McLachlan JA, Korach KS. Developmental pattern of estrogen receptor expression in female mouse genital tracts. Endocrinology 1989, 125 2888-2896
42. Kiang DT, Kollander RE, Thomas T, Kennedy BJ Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 1989; 49.5312-5316.
43. Leclercq G, Legros N, Piccart MJ Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment J Steroid Biochem Mol Biol 1992; 41:545-552
44. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse Cancer Res 1988; 48.812-815
45. Vering A, Vockel A, Stegmuller M, Bender HG Immune-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy J Cancer Res Clin Oncol 1993; 119 415-420
46. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer Cancer 1993; 71:1266-1272
47. Montoya F, Barbazan MJ, Schneider J, Matorras R, Rodriguez-Escudero FJ. Variations in estrogen and progesterone receptor levels after short-term tamoxifen treatment in breast carcinoma Oncology 1992; 49 422-425.
48. Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators Br J Cancer 1993, 68:352-356.
49. Martin PM, Berthois Y, Jensen EV. Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor Proc Natl Acad Sci USA 1988, 85.2533-2537